Hadlima Solution
Product Images NDC 50090-8167

Product Visual Gallery

This gallery contains 68 technical images submitted to the FDA as part of the official labeling for Hadlima (NDC 50090-8167). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Image 01)

A line graph displaying the percentage of ACZ120 responders over time in weeks, comparing two groups: one receiving 40 mg of HADLIMA (adalimumab-bwwd) every other week and a placebo group. The x-axis represents time in weeks, and the y-axis shows the percent of responders, with the treated group showing a higher response rate throughout the study duration.*

FDA Label Image

Figure 2 (Image 02)

Line graph showing percentage of ASA 20 response over 24 weeks comparing Adalimumab (N=208) with placebo (N=107). The x-axis represents time in weeks, and the y-axis shows response percentage, illustrating higher response rates for Adalimumab throughout the period.*

FDA Label Image

Figure 3 (Image 72)

Two line graphs labeled Study UV I and Study UV II depict treatment failure rates over 20 months comparing adalimumab and placebo. Both graphs show treatment failure rate (%) on the y-axis and time in months on the x-axis, with separate curves for placebo and adalimumab treatment groups.*

FDA Label Image

Samsung Logo (Image 03)

FDA Label Image

Organon Logo (Image 04)

Packaging label indicating the manufacturer details for HADLIMA 40 mg/.8mL solution, produced for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ, USA.*

FDA Label Image

Samsung Logo (Image 05)

FDA Label Image

Organon Logo (Image 06)

Label imprint showing the manufacturer information for HADLIMA, indicating it is manufactured for Organon LLC, a subsidiary of ORGANON & Co., located in Jersey City, NJ 07302, USA.*

FDA Label Image

Figure A (Prefilled Syringe)

An instructional diagram labeled 'Figure A' showing the components of a subcutaneous injection device for HADLIMA (adalimumab-bwwd) solution. The parts identified from left to right are needle cap, body with window, flange, and plunger.*

FDA Label Image

Refrigerator (Image 08)

Packaging label of HADLIMA 40 mg/.8mL solution for subcutaneous injection. The label includes the proprietary name HADLIMA and the generic name adalimumab-bwwd. It also shows the A-S Medication Solutions labeler information along with the product NDC 50090-8167. The label is primarily blue and white.*

FDA Label Image

Light (Image 09)

HADLIMA 40 mg/0.8 mL subcutaneous solution carton packaging by A-S Medication Solutions. The front panel features the product name and dosage strength prominently with a white and blue color scheme and a subtle design element in the background.*

FDA Label Image

Caution (Image 10)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection packaging label. The label includes the proprietary name HADLIMA and the generic name adalimumab-bwwd, indicating a human prescription drug. The labeler is A-S Medication Solutions. The packaging is primarily yellow with clear black text.*

FDA Label Image

Container (Image 11)

HADLIMA 40 mg/.8 mL solution for subcutaneous injection carton. The front panel displays the brand name HADLIMA prominently, with the generic name adalimumab-bwwd below it. The package includes dosing strength information and indicates the product is a human prescription drug. The labeler is A-S Medication Solutions. The packaging is primarily white with green accents.*

FDA Label Image

Figure B (Prefilled Syringe)

An instructional illustration labeled Figure B showing a hand wearing a pink wristwatch displaying time, positioned next to a syringe with a needle cover. The image likely demonstrates timing related to the subcutaneous injection process of HADLIMA (adalimumab-bwwd) solution.*

FDA Label Image

Figure C (Prefilled Syringe)

An instructional illustration labeled 'Figure C' showing a prefilled syringe, an alcohol swab packet labeled 70% isopropyl, a red sharps container, and cotton balls or gauze pads (not included in the carton), used together in the administration of HADLIMA (adalimumab-bwwd) subcutaneous solution.*

FDA Label Image

Figure D (Prefilled Syringe)

An instructional illustration showing a hand holding a prefilled syringe for subcutaneous injection. The image highlights three verification checkpoints before use: ensuring the solution is clear, confirming no particles are present, and checking the expiration date. This is related to the administration of HADLIMA (adalimumab-bwwd) solution 40 mg/.8 mL.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional illustration showing suggested subcutaneous injection sites for HADLIMA (adalimumab-bwwd) on a person's abdomen and outer thighs. The image includes a reminder to clean the skin with a 70% isopropyl alcohol swab before injection.*

FDA Label Image

Figure F (Prefilled Syringe)

Illustration showing step in using an injection device for HADLIMA (adalimumab-bwwd) 40 mg/0.8 mL solution for subcutaneous injection. The image depicts hands removing a protective cap from the needle before administration.*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration labeled Figure G showing hands administering a subcutaneous injection with a syringe held at a 45 degree angle to the skin.*

FDA Label Image

Figure H (Prefilled Syringe)

An instructional illustration showing a person administering a subcutaneous injection using a syringe, specifically demonstrating the thumb pressing on the syringe plunger. The image highlights the correct hand positioning for injecting, relevant to the subcutaneous dosage form of HADLIMA (adalimumab-bwwd) 40 mg/.8 mL solution.*

FDA Label Image

Figure I (Prefilled Syringe)

An instructional illustration showing a hand holding a syringe with the needle retracted, indicating proper disposal after use. A red sharps container is visible for safe needle disposal. Text instructs to confirm the needle is retracted and no medicine is leaking, except for a small drop.*

FDA Label Image

Samsung Logo (Image 20)

FDA Label Image

Organon Logo (Image 21)

The image shows a manufacturing statement for the drug HADLIMA (adalimumab-bwwd) 40 mg/0.8 mL solution, subcutaneous, indicating it is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, New Jersey, USA.*

FDA Label Image

Figure A (Autoinjector)

Illustration labeled Figure A showing a prefilled syringe with parts identified including needle cap (green), base, medicine window, and medicine label. The syringe is a device for subcutaneous administration of HADLIMA (adalimumab-bwwd) solution.*

FDA Label Image

Refrigerator (Image 23)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. The image shows a label on a prefilled syringe with blue and white text, including the brand name HADLIMA prominently displayed. The label includes dosage strength and volume. The labeler is A-S Medication Solutions, and the product is identified as adalimumab-bwwd, a human prescription drug.*

FDA Label Image

Light (Image 24)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection, labeled with active ingredient adalimumab-bwwd. The label features a blue and white design with dosage information prominently displayed. The product is manufactured by A-S Medication Solutions. The label includes a barcode and regulatory information.*

FDA Label Image

Caution (Image 25)

HADLIMA 40 mg/.8 mL solution for subcutaneous injection. The vial is clear with a silver and blue cap. The label shows the proprietary name HADLIMA prominently along with the dosage strength 40 mg/.8 mL. The labeler is A-S Medication Solutions. The vial contains a single-dose liquid formulation of adalimumab-bwwd.*

FDA Label Image

Container (Image 26)

HADLIMA 40 mg/.8 mL solution for subcutaneous injection packaging label. The label includes the product name, strength, dosage form, and administration route. It prominently features the labeler A-S Medication Solutions and displays the product NDC 50090-8167. The design uses blue and white colors with clear typography.*

FDA Label Image

Figure B (Autoinjector)

An instructional illustration labeled Figure B showing a wristwatch displaying the time and a subcutaneous injection device nearby, likely to guide timing for administration or usage instructions related to HADLIMA injection.*

FDA Label Image

Figure C (Autoinjector)

An illustration labeled Figure C showing a HADLIMA autoinjector syringe at the top. Below are an alcohol swab packet labeled 70% isopropyl, a red sharps container labeled 'SHARPS CONTAINER', and cotton balls or gauze pads. Text notes that the alcohol swab, sharp container, and cotton ball or gauze are not included in the carton.*

FDA Label Image

Figure D (Autoinjector)

Illustration showing a hand holding a HADLIMA prefilled syringe labeled as 40 mg/0.8 mL solution for subcutaneous use. The image highlights inspecting the syringe barrel for clarity and absence of particles, as well as checking the expiration date before use.*

FDA Label Image

Figure E (Autoinjector)

Illustration showing recommended injection sites for subcutaneous administration of HADLIMA (adalimumab-bwwd) solution. The diagram highlights the abdomen and front thighs as injection areas with accompanying text advising to clean the skin before injection using an alcohol swab.*

FDA Label Image

Figure F (Autoinjector)

An instructional illustration labeled Figure F shows two hands; one holding a pen-like syringe device, and the other holding a cap being pulled off the syringe. A blue arrow indicates the direction of removing the cap from the syringe tip.*

FDA Label Image

Figure G (Autoinjector)

An instructional illustration showing a hand holding a syringe vertically above a surface, with a blue downward arrow indicating the motion to press or inject. The text 'Click' with a check mark is shown near the top of the syringe, suggesting a step in the injection process.*

FDA Label Image

Figure H (Autoinjector)

An instructional illustration labeled Figure H showing a hand holding a syringe with the thumb pressing down. A magnified inset highlights the plunger of the syringe. The word 'Click' with a checkmark is placed near the thumb, indicating an action to press or click the syringe plunger downward.*

FDA Label Image

Figure I (Autoinjector)

An instructional illustration showing a hand holding a syringe with a yellow medicine window, indicating a correct dosing with no medicine leakage. The image also depicts a red sharps disposal container labeled "SHARPS CONTAINER" suggesting proper disposal of used syringes.*

FDA Label Image

Samsung Logo (Image 35)

FDA Label Image

Organon Logo (Image 36)

The image displays a product label segment for HADLIMA (adalimumab-bwwd) solution, 40 mg/0.8 mL, manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ, USA. The label features the Organon & Co. name and logo.*

FDA Label Image

Figure A (Prefilled Syringe)

Illustration labeled Figure A showing parts of a prefilled syringe or injection device. Labeled components include needle cap, body with window, flange, and plunger, indicating the main parts of the subcutaneous injection device for HADLIMA (adalimumab-bwwd) solution.*

FDA Label Image

Refrigerator (Image 38)

HADLIMA 40 mg/.8 mL solution for subcutaneous injection carton and prefilled syringe packaging by A-S Medication Solutions. The package includes one 0.8 mL prefilled syringe containing 40 mg of adalimumab-bwwd.*

FDA Label Image

Light (Image 39)

HADLIMA 40 mg/0.8 mL solution in a single-dose prefilled pen for subcutaneous administration, labeled by A-S Medication Solutions. The packaging is predominantly white with blue and gray design elements, including the product name and strength prominently displayed.*

FDA Label Image

Caution (Image 40)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection. The label displays the proprietary name HADLIMA prominently with the generic name adalimumab-bwwd below. It includes dosage form and route information (solution, subcutaneous) and shows the labeler as A-S Medication Solutions. The packaging is primarily white with green and gray text.*

FDA Label Image

Container (Image 41)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection carton by A-S Medication Solutions. The packaging is primarily white with red and black text, featuring the proprietary name prominently and including the active ingredient adalimumab-bwwd. The label includes dosing information and the product NDC 50090-8167.*

FDA Label Image

Figure B (Prefilled Syringe)

An instructional illustration showing a hand wearing a pink wristwatch next to a syringe. This likely depicts a step related to timing or administration of a subcutaneous injection, relevant to HADLIMA (adalimumab-bwwd) solution use.*

FDA Label Image

Figure C (Prefilled Syringe)

An instructional illustration labeled Figure C shows a prefilled syringe, an alcohol swab packet, a sharp container, and cotton balls or gauze. A note indicates that the alcohol swab, sharp container, and cotton ball or gauze are not included in the carton.*

FDA Label Image

Figure D (Prefilled Syringe)

Illustration showing a hand holding a syringe with instructions to verify if the solution is clear, confirm there are no particles, and check the expiration date. The diagram is labeled as Figure D, indicating preparation or inspection steps for a subcutaneous injection.*

FDA Label Image

Figure E (Prefilled Syringe)

An instructional illustration labeled Figure E showing a human torso with a marked area on the abdomen and lower thighs, suggesting recommended injection sites. The image includes a graphic of an alcohol swab packet labeled 70% isopropyl and a reminder text stating 'Clean your skin.' This diagram provides guidance on skin preparation and injection site locations for subcutaneous administration.*

FDA Label Image

Figure F (Prefilled Syringe)

An instructional illustration showing a pair of hands performing a step in syringe preparation. One hand holds the syringe, while the other hand is removing the needle cap by pulling it straight off as indicated by a blue arrow.*

FDA Label Image

Figure G (Prefilled Syringe)

An instructional illustration showing a hand injecting a subcutaneous solution at a 45 degree angle into the skin of another hand, demonstrating proper injection technique for a subcutaneous drug like HADLIMA (adalimumab-bwwd).*

FDA Label Image

Figure H (Prefilled Syringe)

An instructional illustration showing a hand administering a subcutaneous injection with a syringe into the forearm of another hand. The syringe plunger is being pressed down by a thumb, indicated by an arrow, demonstrating the injection technique for a subcutaneous solution medication.*

FDA Label Image

Figure I (Prefilled Syringe)

An instructional illustration titled Figure 1 showing a hand holding a syringe with the needle retracted and a small drop of medicine visible at the tip. Text beside the image advises that the dose is correct if the needle is retracted and no medicine leaks out, with a note that a small drop is acceptable. A red sharps container is shown to the left of the hand.*

FDA Label Image

Samsung Logo (Image 50)

FDA Label Image

Organon Logo (Image 51)

Label panel for HADLIMA (adalimumab-bwwd) solution, 40 mg/0.8 mL, indicating manufacturing by Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ 07302, USA, for labeler A-S Medication Solutions.*

FDA Label Image

Figure A (Autoinjector)

An illustration labeled Figure A showing the parts of a subcutaneous injection syringe. The syringe components are identified as needle cap, base, medicine window, and medicine label from left to right.*

FDA Label Image

Refrigerator (Image 53)

HADLIMA 40 mg/0.8 mL subcutaneous solution is presented in a single-use prefilled syringe with a clear barrel and orange safety needle cap. The syringe contains a colorless to pale yellow liquid. The label includes dosage information and usage instructions, reflecting the product by A-S Medication Solutions.*

FDA Label Image

Light (Image 54)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection vial with a pink cap. The vial label shows the proprietary name HADLIMA and strength 40 mg/0.8 mL, along with other labeling details. The product is labeled by A-S Medication Solutions.*

FDA Label Image

Caution (Image 55)

The image shows a rectangular carton for HADLIMA 40 mg/0.8 mL solution. The product name HADLIMA is prominently displayed along with the indication that it contains adalimumab-bwwd. The package is for subcutaneous use and is labeled as a human prescription drug. The labeler is A-S Medication Solutions, and the product NDC 50090-8167 is visible on the carton.*

FDA Label Image

Container (Image 56)

HADLIMA 40 mg/0.8 mL solution for subcutaneous injection in a single-dose prefilled syringe. The label shows the brand name HADLIMA prominently, the active ingredient adalimumab-bwwd, dosage strength 40 mg per 0.8 mL, and indicates it is a human prescription drug. The labeler is A-S Medication Solutions with NDC 50090-8167.*

FDA Label Image

Figure B (Autoinjector)

Figure B shows an illustration of a wrist wearing a pink watch displaying time and a blue and white pen-style device, likely an auto-injector, positioned to the right of the wrist. This appears to be an instructional figure related to timing or use of the device.*

FDA Label Image

Figure C (Autoinjector)

An illustration labeled Figure C showing the HADLIMA 40 mg/.8 mL autoinjector pen for subcutaneous use. The image also depicts an alcohol swab, a sharps container, and cotton balls or gauze, with a note that these accessories are not included in the carton.*

FDA Label Image

Figure D (Autoinjector)

An instructional illustration showing a hand holding a HADLIMA PushTouch 40 mg/.8 mL prefilled injection pen. The image highlights checking the medication for no particles and clarity, and verifying the expiration date before use.*

FDA Label Image

Figure E (Autoinjector)

An instructional illustration showing areas on the front of the torso and thighs suitable for subcutaneous injection. Included is an image of an alcohol swab packet labeled "Alcohol Swab 70% Isopropyl" accompanied by the reminder to clean the skin before injection.*

FDA Label Image

Figure F (Autoinjector)

An instructional illustration showing two hands demonstrating the removal of the cap from a pre-filled syringe or injection pen, with an arrow indicating the direction to pull the cap off. The image is likely part of a usage guide for subcutaneous injection.*

FDA Label Image

Figure G (Autoinjector)

An instructional illustration labeled 'Figure G' showing a hand holding an injection pen vertically above the skin, ready to administer a subcutaneous injection, with a downward arrow indicating the direction of insertion and a 'Click' sound cue noted.*

FDA Label Image

Figure H (Autoinjector)

An instructional illustration labeled Figure H shows a hand holding a device vertically with a close-up inset highlighting an orange indicator line. The inset demonstrates a correct 'Click' action, indicating proper device use or activation, likely related to administering HADLIMA solution subcutaneously.*

FDA Label Image

Figure I (Autoinjector)

Illustration showing a hand holding a syringe with HADLIMA injection, positioned over a sharps container. The image instructs that the dose is confirmed if the medicine window on the syringe is yellow and no medicine has leaked out, with a note that a small drop is acceptable.*

FDA Label Image

Samsung Logo (Image 65)

FDA Label Image

Organon Logo (Image 66)

This image shows a manufacturing information label for HADLIMA (adalimumab-bwwd) solution 40 mg/0.8 mL. It states the product is manufactured for Organon LLC, a subsidiary of Organon & Co., located in Jersey City, NJ 07302, USA.*

FDA Label Image

Label Image (Lbl500908167)

Label for HADLIMA PushTouch (adalimumab-bwwd) 40 mg/0.8 mL solution, subcutaneous use. The label includes storage instructions (refrigerate at 36 to 46°F), packaging information (2 single-dose prefilled autoinjectors), dosage, and distributor details for A-S Medication Solutions, Libertyville, IL 60048.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.